Cencora traded @4.36 billion on February 26. Trading volume increased 69.21% compared to the previous trading day.

K-LinePoet · 2026-03-24T03:44:27+00:00

On February 26, 2026, Cencora (COR) recorded trading volume of $436 million, up 69.21% from the previous period, with the stock price rising to $366.65, representing a year-to-date gain of 8.56%. The company's financial report shows that for Q1 of fiscal year 2026, revenue reached $859.32 billion, reflecting year-over-year growth of 5.45%.

K-LinePoet

2026-03-24 03:44:27

Abstract generation in progress

On February 26, 2026, Cencora (COR), a healthcare and nursing product distributor, had a trading volume of $436 million, ranking 319th among U.S. stocks that day. The trading volume increased by 69.21% compared to the previous day, with a total of 1.0245 million shares traded.

Cencora (COR) rose 1.00% on February 26, 2026, closing at $366.65. Over the past five trading days, the stock increased by 2.10%, for the month of February it gained 2.07%, and since the beginning of the year, it has risen 8.56%. Over the past 52 weeks, it has increased by 46.28%.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies if listed for less than 1 month or fewer than 5 trading days).

Cencora (COR)	Trading Volume / USD	Change from Previous Day	Volume
February 26, 2026	$436 million	+69.21%	1.0245 million
February 25, 2026	$257 million	-24.49%	707,800
February 24, 2026	$341 million	+1.55%	935,100
February 23, 2026	$336 million	-11.29%	919,500
February 20, 2026	$378 million	+47.85%	1.0513 million

Cencora released its Q1 FY2026 earnings report on February 4, 2026. Revenue for the period from October 1, 2025, to December 31, 2025, was $85.932 billion, a 5.45% increase year-over-year. Net income was $566 million, up 14.67% year-over-year.

Cencora, Inc. is one of the world’s largest pharmaceutical procurement and distribution service companies, helping healthcare providers, pharmaceutical, and biotech manufacturers improve patient access to products and enhance patient care. The company offers innovative programs and services aimed at increasing the efficiency and effectiveness of the pharmaceutical supply chain in human and animal health. Specifically, it provides comprehensive branding, specialty brands, generic drugs, over-the-counter medical products, home healthcare supplies and equipment, and related services to healthcare providers in the U.S. and select global markets. These include acute care hospitals and health systems, independent and chain retail pharmacies, mail-order pharmacies, clinics, long-term care and alternative site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other clients. Additionally, the company offers various related services to healthcare providers and pharmaceutical manufacturers, including data analytics, outcomes research, reimbursement and drug consulting, niche premium logistics, inventory management, pharmacy automation, pharmacy management, and packaging solutions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes